MedGenome has introduced a CNS tumor Methylation Classifier Test (MCT) in India, enabling precise classification of over 90 brain and CNS tumors. Complementing histology, the test uses DNA methylation profiling to detect molecular changes, predict treatment response, and align with WHO’s 2021 guidelines.
